{"nctId":"NCT01641822","briefTitle":"Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF","startDateStruct":{"date":"2012-12"},"conditions":["Cystic Fibrosis"],"count":107,"armGroups":[{"label":"AZLI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: AZLI","Drug: Tobramycin inhalation solution"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to match AZLI","Drug: Tobramycin inhalation solution"]}],"interventions":[{"name":"AZLI","otherNames":["Cayston®"]},{"name":"Placebo to match AZLI","otherNames":[]},{"name":"Tobramycin inhalation solution","otherNames":["TOBI®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of CF\n* Presence of PA in 2 lower respiratory tract cultures in the 12 months prior to screening\n* Forced expiratory volume (FEV)1 ≥ 25 and ≤ 75% predicted\n* History of 1 hospitalization or 1 course of IV antibiotics for an acute respiratory exacerbation in the 12 months prior to screening\n\nExclusion Criteria:\n\n* Concurrent use of oral, IV or inhaled antibiotics at enrollment\n* Concurrent hospitalization at enrollment\n* History of local or systemic hypersensitivity to monobactams or aminoglycoside antibiotics or history of aminoglycoside antibiotic associated toxicity","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Protocol-defined Exacerbations (PDE) From Baseline Through Week 24","description":"PDEs were characterized by a change or worsening from baseline of 1 or more documented signs or symptoms (decreased exercise tolerance, increased cough, increased sputum or chest congestion, decreased appetite, or other signs or symptoms) associated with the use of non-study IV or inhaled antibiotics and be verified by a blinded independent adjudication committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.309","spread":null},{"groupId":"OG001","value":"1.762","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Actual Change From Baseline in FEV1 % Predicted Across All Courses of AZLI/Placebo Treatment (Weeks 4, 12 and 20)","description":"FEV1 % predicted is defined as FEV1 of the patient divided by the average FEV1 in the population for any person of similar age, sex and body composition. The adjusted mean is from a mixed-effect model repeated measures (MMRM) analysis. The model includes terms for baseline value, previous exacerbations (1, 2, ≥ 3), treatment, visit (categorical), and treatment by visit interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":"0.674"},{"groupId":"OG001","value":"0.04","spread":"0.658"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Used Non-study IV or Inhaled Antibiotics for PDEs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"55.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Protocol-defined Pulmonary Exacerbation","description":"The time to first protocol-defined pulmonary exacerbation was calculated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"140.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Hospitalizations for a Respiratory Event","description":"The rate of hospitalizations for a respiratory event per participant year was calculated using negative binomial regression analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.043","spread":null},{"groupId":"OG001","value":"1.624","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline in the CFQ-R Respiratory Symptom Scale (RSS) Score Across All Courses of AZLI/Placebo Treatment (Weeks 4, 12 and 20)","description":"Respiratory symptoms (eg, coughing, congestion, wheezing) were assessed with the Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS). The range of scores (units) was 0 to 100 with higher scores indicating fewer symptoms. The adjusted mean is from a mixed-effect model repeated measures (MMRM) analysis. The model includes terms for baseline value, previous exacerbations (1, 2, ≥ 3), treatment, visit (categorical), and treatment by visit interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.736"},{"groupId":"OG001","value":"-2.06","spread":"1.629"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":107},"commonTop":["Cough","Sputum increased","Dyspnoea","Fatigue","Chest discomfort"]}}}